Treatment and Assessment of Negative Symptoms in Schizophrenia

Negative symptoms in schizophrenia—characterised by diminished emotional expression, reduced motivation and social withdrawal—are among the most disabling aspects of the illness. Unlike positive symptoms, which respond relatively well to dopaminergic antipsychotics, negative symptoms persist in many patients and predict poor functional and vocational outcomes. Assessment relies on both clinician-rated and patient-reported scales that capture domains such as avolition, alogia, anhedonia and affective flattening. Traditional instruments include the Positive and Negative Syndrome Scale (PANSS) and the Scale for the Assessment of Negative Symptoms (SANS), while newer measures such as the Brief Negative Symptom Scale (BNSS) and the Clinical Assessment Interview for Negative Symptoms (CAINS) offer improved granularity and reliability. Treatment approaches span pharmacological, psychosocial and neuromodulation strategies. Pharmacological efforts have moved beyond dopamine antagonism to explore glutamatergic modulators, cholinergic agents and adjunctive antidepressants, yet few interventions yield consistent, clinically meaningful benefits. Psychosocial interventions—cognitive remediation, social skills training and exercise programmes—demonstrate modest effect sizes, often as part of multimodal rehabilitation. Emerging work highlights the need for biomarker-driven, personalised regimens and earlier intervention to mitigate the long-term impact of negative symptoms on quality of life.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Treatment and Assessment of Negative Symptoms in Schizophrenia publication trend

The graph below shows the total number of articles in treatment and assessment of negative symptoms in schizophrenia across all publications each year (not limited to Nature Index journals).

Technical terms

Negative symptoms: Core deficits in motivation, emotional expression and social engagement observed in schizophrenia.

Primary negative symptoms: Intrinsic schizophrenia-related deficits not attributable to other factors such as medication side effects or depression.

Secondary negative symptoms: Apparent negative features resulting from factors like antipsychotic side effects, social deprivation or concurrent mood disorders.

Brief Negative Symptom Scale (BNSS): A clinician-rated instrument assessing five domains of negative symptoms with enhanced reliability and sensitivity.

Clinical Assessment Interview for Negative Symptoms (CAINS): A semi-structured interview designed to capture experiential and expressive components of negative symptoms.

Avolition: A reduction in the initiation and persistence of goal-directed activities.

Anhedonia: Diminished capacity to experience pleasure from normally enjoyable activities.

Cognitive remediation: A structured behavioural therapy aimed at improving neurocognitive processes to support functional recovery.

References

1. IUPHAR review – Novel therapeutic targets for schizophrenia treatment: A translational perspective. Pharmacological Research (2025).
2. Efficacy of low-dose risperidone in combination with sertraline in first-episode drug-naïve patients with schizophrenia: a randomized controlled open-label study. Journal of Translational Medicine (2023).
3. Psychosocial and behavioural interventions for the negative symptoms of schizophrenia: a systematic review of efficacy meta-analyses. The British Journal of Psychiatry (2023).
4. An Assessment of Five (PANSS, SAPS, SANS, NSA-16, CGI-SCH) commonly used Symptoms Rating Scales in Schizophrenia and Comparison to Newer Scales (CAINS, BNSS). Journal of Addiction Research & Therapy (2017).
5. Negative symptoms in schizophrenia: Newly emerging measurements, pathways, and treatments. Schizophrenia Research (2023).